Safety and efficacy of a 100 % dimethicone pediculocide in school-age children by Erin Speiser Ihde et al.
RESEARCH ARTICLE Open Access
Safety and efficacy of a 100 % dimethicone
pediculocide in school-age children
Erin Speiser Ihde1*, Jeffrey R. Boscamp2, Ji Meng Loh3 and Lawrence Rosen1
Abstract
Background: Head lice most commonly affect children, ages 3 to 11. Concerns exist about the safety and efficacy
of pesticide-based treatments. Published studies suggest dimethicone is a potentially safe and effective non-toxic
treatment, but have not evaluated 100 % dimethicone in a pediatric population. The objectives were to evaluate
the efficacy and safety of 100 % dimethicone for the treatment of head lice in children, monitored by school nurses.
Methods: This was a multi-site, open-label study of a 100 % dimethicone gel for the treatment of head lice in a
pediatric population. Children (ages 3–12) suspected of infestation with head lice were evaluated by school
nurses at six schools and daycare programs in New York and New Jersey. Inclusion criteria were presence of at
least three live lice, or one live louse and 10 viable eggs (eggs found within 1.27 cm of the scalp) and no use of
any head lice treatment within four weeks of enrollment. Counts of live lice and viable eggs found in 58 subjects
were tracked at baseline (Day 0) and on Day 1, Day 7, and Day 14 after treatment.
Results: After 1 day of treatment with 100 % dimethicone, 98.30 % of subjects were free of live lice and 55.20 %
were free of viable eggs. On day 14, 96.50 % were still free of live lice, and 80.70 % were free of viable eggs.
All subjects were monitored by the school nurse at baseline and throughout the study period for adverse effects,
including scalp erythema, excoriation, flaking and edema. There was one adverse event of skin irritation lasting
10 min, and no serious adverse events reported. Overall, scalp conditions improved from the baseline: 10 subjects
(17.5 %) reported mild to moderate scalp erythema on day 1, compared with only one subject (1.7 %) on day 14;
8 subjects (14.3 %) reported mild scalp excoriation on day 1, with none reporting on day 14.
Conclusions: 100 % dimethicone was found to be a safe and highly effective treatment for pediatric head lice.
Because dimethicone avoids pesticide exposure and resistance issues, dimethicone should be considered as a
first-line treatment for head lice.
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Background
Head lice, or Pediculus humanus capitis, cause an esti-
mated 6 to 12 million infestations per year in the U.S.,
most commonly affecting children 3 to 11 years of age [1].
Head lice affect all socio-economic groups. Infestations
spread regardless of the cleanliness of a home or school
environment, or of personal hygiene. It is a significant
public health issue due to the high anxiety for children
and parents associated with infestation, as well as missed
school days. Despite the American Academy of Pediatrics’
recommendation not to restrict infested children from
school, there are districts that continue to have a no-nit
policy and guardians who keep children out of school [2].
The most common treatments are pesticide-based,
over-the-counter remedies containing permethrin (1 %)
or other pyrethroid insecticides. Prescription-only op-
tions include high-dose permethrin (5 %), malathion
(0.5 %), benzyl alcohol lotion (5 %), ivermectin lotion
(0.5 %) and spinosad suspension (0.9 %) [3].
Pesticide-based treatments are coming under increasing
scrutiny regarding safety and efficacy. Specifically, exposures
to neurotoxic pesticides have been linked to lowered IQ,
diminished attention span, other neurodevelopmental issues
and childhood cancers [4–6]. Additionally, studies have found
insecticide resistance in head lice, [7–12] particularly to per-
methrin and malathion. Given these concerns, an effective
and safe alternative pesticide-free treatment is desirable.
Dimethicone (also spelled dimeticone) is a silicone-
based polymer that works mechanically to lubricate hair
to aid the removal of nits and lice, while physically
occluding the respiratory system of the louse. Burgess
found that dimethicone potentially eliminates the pesti-
cide-resistance issue as “the blockage [of dimethicone
coating the louse] inhibits water excretion, which causes
physiological stress that leads to death either through
prolonged immobilisation or, in some cases, disruption
of internal organs such as the gut” [13].
Several published trials have established plausibility for
the use of dimethicone in pediatric lice treatment, dem-
onstrating it may be more effective than conventionally-
recommended pesticide-based pediculocides [13–26].
These studies include concentrations of 4-96 % dimethi-
cone in vivo. Only one published trial evaluated the in vitro
ovicidal efficacy of 100 % dimethicone. No previously
published study has examined the in vivo safety and
efficacy of a 100 % dimethicone-based treatment for
head lice. Dimethicone-based treatments are commonly
used in the European Union and even recommended as
a first-line treatment in some Australian jurisdictions
[27]. However, they are not a first line treatment in the
U.S. and are not listed as one of the recommended
treatments in the American Academy of Pediatrics’ (AAP)
2012 Red Book® [28]. Dimethicone is listed in the AAP's
2015 Clinical Report as an alternative treatment [29].
The objectives of this study were to evaluate the effi-
cacy and safety of 100 % dimethicone gel for the topical
treatment of head lice in a pediatric, school-centered
population.
Methods
This was a multi-site, open-label study of a 100 %
dimethicone gel [LiceMD, manufactured by Combe, Inc,
subsequently renamed as LiceMD Pesticide Free] for the
treatment of head lice in children. The 100 % dimethicone
liquid has a viscosity of 350 centistokes and is composed
of a single viscosity polymer.
Children (ages 3–12) suspected of infestation with
head lice were evaluated from May 2009 to June 2013 by
school nurses at six schools and daycare programs in
New York and New Jersey who were trained in all study
procedures. Subjects were referred to the school nurse for
head lice evaluation by school staff members, parents/
guardians, or were diagnosed as part of routine school
head checks. Written informed consent for participation
in the study was obtained from the subject’s parent or
guardian. Additionally, each child nine years of age or
older was asked to read and sign an assent form if he or
she agreed to participate in the study.
Children could be included as subjects if they met the
following criteria as determined by the school nurses,
who were trained in how to detect lice using a standard
visual census technique: presence of at least three live
lice or one live louse and 10 viable eggs (eggs found
within 1.27 cm of the scalp). The subject could not have
used any head lice treatment within four weeks of enroll-
ment, as reported to the nurse by the parent/guardian. A
child could be enrolled more than once in the study only
if he or she had not used any other lice treatment or home
remedy within the past four weeks. Four subjects were
each re-enrolled once in the study. Children were ex-
cluded if they had no hair, extremely short hair, a chronic
scalp disorder, or were currently taking an antibiotic.
Nurses were instructed to ask the parent/guardian about
antibiotic use.
Once children were enrolled, guardians were given a
copy of the product use directions, the test product, and
a lice removal comb. The guardian treated the child at
home with the product according to the manufacturer’s
instructions. Treatment procedures were as follows:
First, apply the product to dry hair, then wait 10 min.
Next, with product still in the hair, separate hair into
small sections and comb hair to remove lice and eggs.
LiceMD® products contain a patented comb specially
designed to remove lice and their eggs from hair [30].
Finally, shampoo hair thoroughly with regular shampoo
and warm water. After treating the child, the guardian
completed the “First Application” Parent Diary and
Observation Form in the treatment log.
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The first school day following the initial application of
dimethicone, the school nurse examined the subject,
checking for live lice and viable eggs while visually
inspecting the condition of the child’s scalp. If any live
lice were found (or if the child had nits and the child’s
school had a “no nits” policy), the guardian was notified
and advised to immediately apply a second dimethicone
treatment. If a second application was done, the guardian
was asked to complete the “Second Application” Parent
Diary and Observation Form. If any scalp condition score
was higher (worse) than the baseline score, the child was
checked daily on school days until the irritation resolved.
If a third application was needed, the same procedure was
followed, and the guardian was asked to complete the
“Third Application” page of the treatment log.
The guardian was asked to re-inspect the child’s scalp
and hair each day for lice, eggs and nits for 13 days. If
lice or viable eggs were seen, the parent was asked to
notify the school nurse. The school nurse confirmed the
presence and instructed the parent to treat.
On all subjects, seven days (±2 days) and fourteen days
(±2 days) after the initial application of treatment, the
school nurse conducted a head check for lice and eggs
and completed an Egg/Lice/Scalp Condition Form. If the
nurse noticed any live lice, the guardian was notified and
asked to do another treatment.
Fourteen days (±2 days) after the first treatment, the
school nurse conducted another head check on the
treated child and completed another Egg/Lice/Scalp
Condition Form. If there was still a live lice infestation,
the school nurse notified the guardian and discussed
further treatment options. Guardians then completed
the fourteen day product use questionnaire.
To comply with best practices in ethical approval and
consent, this research study was conducted in accordance
with the Declaration of Helsinki and was approved prior to
the commencement by the HackensackUMC Institutional
Review Board (HIRB protocol number Pro00000685). In-
formed consent was obtained from each participant’s parent
or guardian prior to enrollment. The signed consent docu-
ment included a statement informing parents/guardians
that their child’s identity will remain confidential if the
results of the trial are published.
The protocol and clinical dataset will be made available
upon request to any scientist wishing to use them for
non-commercial purposes.
For the statistical analysis, the live lice and viable egg
data were analyzed separately, using logistic regression
to model the presence or absence of lice/eggs as a
function of time, defined by days of treatment, and the
other subject characteristics. The correlation between
lice/egg counts for each subject on different days was




A total of 58 subjects were included in the study. Subject
characteristics included age, gender, hair amount (thick-
ness), hair length and number of applications. The subjects
were aged between 3.5 and 13 years old, with a mean of
nearly 7 years (6.98) and a standard deviation of 1.73, as
summarized in Fig. 1. Although study eligibility called for
subjects ages 3–12, one 13 year old student was inadvert-
ently enrolled. Statistical analysis showed that age did not
affect the rate of decrease in the presence of viable eggs
due to treatment, i.e. there was no difference in the effect-
iveness of the treatment with age.
Definitions for hair amount and hair length were not
supplied on the questionnaire and were determined by
the school nurse and/or the parent filling out the form
with the nurse’s assistance. The inclusion of these
characteristics was mainly to explore the possibility of
varying product effectiveness with these characteristics.
Fig. 1 Subject age
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No significant differences in effectiveness were found with
respect to gender, age or hair characteristics. Table 1
displays summary statistics of the data.
We enrolled 97 subjects from six schools, resulting in
58 evaluable charts. The 39 subjects not evaluable were
excluded due to reasons detailed in Table 2, including
issues with documentation (incomplete or missing study
forms) or not meeting inclusion criteria.
The study included a comparison group in which
those opting to use a treatment other than LiceMD
could enroll and still be followed for outcomes according
to the same criteria in the experimental arm. All subjects
chose to enroll in the experimental arm of the study.
Efficacy
The data consist of counts of live lice and viable eggs
found in 58 subjects at baseline (Day 0) and on Day 1,
Day 7, and Day 14 after treatment as shown in Fig. 2.
After one day of treatment, 98.30 % of subjects (57 of
58) were free of live lice and 55.20 % (32 of 58) were free
of viable eggs. At diagnosis, 55 subjects had viable eggs
with three subjects meeting enrollment criteria for three
or more live lice. On day 14 of the study, 96.50 % of
subjects (55 of 57) were still free of live lice, and 80.70 %
(46 of 57) were free of viable eggs. If a child was still
found with live lice on day 14, the school nurse notified
the guardian to discuss further treatment options, as
subjects could not immediately re-enroll in the study.
The removal of eggs was facilitated by the viscosity of
the product and the lice comb provided, which together
eased removal.
Of the 58 subjects, 43 received a total of one treat-
ment, ten received two treatments and five received
three treatments [Table 1]. Subjects received a second or
third treatment if lice or viable eggs were confirmed by
the school nurse.
Safety
All subjects were monitored by the school nurse at base-
line and throughout the study period for adverse effects,
including scalp erythema, excoriation, flaking and edema.
One adverse event was reported by a parent/guardian dur-
ing the study, which was transcribed by the school nurse
on the Adverse Event Report form as “Irritation on cheek
at time of shampoo application” which occurred “10 min
after shampoo was washed off.” The nurse also reported
that the irritation lasted 10 min and that no medical atten-
tion was needed. There were no reports of significant
adverse events during the study. Overall, scalp conditions
as assessed by the school nurse improved during the two
week study period: 10 subjects (17.5 %) reported mild to
moderate scalp erythema on day 1, compared with only
one subject (1.7 %) on day 14; 8 subjects (14.3 %) reported
mild scalp excoriation on day 1, with none reporting
on day 14.
Discussion
This study demonstrates the efficacy and short-term
safety for the topical use of 100 % dimethicone for
treating pediatric pediculosis. While prior studies have
shown efficacy for dimethicone-containing products, to
our knowledge this is the first study to document the in
vivo safety and efficacy for 100 % dimethicone. Addition-
ally, this study design utilized school and daycare set-
tings to evaluate children for head lice, which is of
practical importance as many children with lice are iden-
tified and followed by school nurses. There were several
limitations for this study: this was an open label single
arm design with no comparison group. Additionally, this
study had a short term assessment for adverse events.
Limitations
Originally enrollment was estimated to be 200 subjects,
as determined by a questionnaire distributed to the
school nurses, asking the approximate number of head
lice cases per school year. The study team then esti-
mated the number of expected cases presenting at each
participating school during the anticipated enrollment
Table 1 Subject characteristics
Variable Values Number of subjects
Gender Female 45
Male 13
Hair amount Thin 14
Medium 23
Thick 20
Hair length Short 15
Long 38
Very long 5
Final Number of treatment applications 1 43
2 10
3 5
Table 2 Subject exclusions
Reason Number of participants
Protocol was not Followed at Enrollment 5
Protocol was not Followed during Study 1
Documentation Issue at Enrollment 1
Documentation Issue during Study 10
Did not have Live Lice 8
Had another Treatment during the Study 3
Did not meet Inclusion Criteria 6
Did not Return to School 5
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period from May 2009 through June 2011. This enrollment
period was later extended to enroll additional subjects, be-
cause only six schools out of 19 actively enrolled subjects
and the number of subjects enrolled at each school was less
than anticipated. School nurses encountered multiple
challenges including limitations with communicating
instructions and follow-up with the parents/guardians.
The nurses also encountered time restrictions due to
high student volume in some schools, which at times
proved challenging to complete the necessary amount of
study paperwork. The study necessitated many volunteer
hours from participating school nurses. Efforts to keep
school nurses engaged in the study and reminded of proto-
col procedures included regular e-newsletters and updates,
phone calls and in-person visits by the study coordinator
and research nurse to assess needs and answer questions.
Study enrollment concluded in June 2013. Funding re-
strictions limiting enrollment time occurred in Decem-
ber 2010 when the sponsor was purchased by another
company and discontinued funding this research. At that
time, The Deirdre Imus Environmental Health Center®
at Hackensack University Medical Center continued
needed funding until the study’s conclusion.
Conclusions
A 100 % dimethicone product is a safe and highly effective
head lice treatment for children and may serve as a poten-
tially less toxic and less resistance prone alternative to
pesticide-containing products. Given its safety and efficacy
record, dimethicone should be considered as a first-line
treatment for pediatric head lice.
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